Online citations, reference lists, and bibliographies.
← Back to Search

Blefarospasmo Essencial E Espasmo Hemifacial: Características Dos Pacientes, Tratamento Com Toxina Botulínica A E Revisão Da Literatura

S. Schellini, Olívia Matai, T. Z. Igami, C. Padovani, C. Padovani
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE: To evaluate the characteristics of the essential blepharospasm and hemifacial spasm patients and the feasible treatment with botulinum toxin A. METHODS: Thirty-four essential blepharospasm or hemifacial spasm patients were evaluated according to gender, ocular complaint, time of disease, treatment outcome and complications. RESULTS: Age median was 63 years and the mean was 61 years, with no difference regarding sex; 66.66% of the patients had hemifacial spasm and 33.33%, essential blepharospasm. Many patients complained of dry eye associated with involuntary spasm. Botulinum toxin A showed a positive outcome in 91.30% of the treated patients and complications observed after treatment were eyelid ptosis (8.33%) and buccal angle deviation (8.33%). CONCLUSION: Essential blepharospasm and hemifacial spasm occurred in the elderly, of both sexes. Treatment with botulinum toxin A was useful, with very low complication rates.
This paper references
Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
A. Thussu (1999)
[Indications and management of botulinum toxin].
C. Singer (1999)
10.1034/j.1600-0404.2001.00109.x
Quality of life in patients with blepharospasm
O. Tucha (2001)
10.1136/BJO.80.12.1073
Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
J. Mauriello (1996)
10.1016/0002-9394(85)90228-4
Treatment of blepharospasm with botulinum toxin.
E. A. Tsoy (1985)
[Applications of the botulinum A toxin].
Magdolna Zajácz (2003)
10.1038/eye.1988.79
The significance of ophthalmological symptoms in idiopathic blepharospasm
J. S. Elsron (1988)
10.1590/S0004-282X1997000400006
Experiência com aplicação de toxina botulínica A em 115 pacientes
L. A. Andrade (1997)
10.1111/j.1600-0404.1996.tb07053.x
Botulinum toxin A injection in the treatment of hemifacial spasm
R. S. Chen (1996)
10.1038/eye.2000.86
Riolan's muscle: Action and indications for botulinum toxin injection
I. Mackie (2000)
10.1097/00002341-199809000-00002
Blepharospasm: Past, Present, and Future
R. Anderson (1998)
10.1007/s00266-002-2030-x
Indications and Limitations for the Use of Botulinum Toxin for the Treatment of Facial Wrinkles
M. Sarrabayrouse (2002)
10.1097/00002341-199911000-00003
A novel mechanism for benign essential blepharospasm.
J. McCann (1999)
10.7326/0003-4819-129-3-199808010-00011
Botulism in the United States: A Clinical and Epidemiologic Review
R. Shapiro (1998)
10.1146/ANNUREV.MICRO.53.1.551
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
E. Johnson (1999)
[Current indications for the treatment with botulin toxin].
A. Kohler (2001)
10.1136/JNNP.60.6.704
Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.
J. Jankovic (1996)
10.1177/112067210301300401
Treatment of Blepharospasm with Botulinum Neurotoxin Type A: Long-Term Results
P. Calace (2003)
[Blepharospasm and hemifacial spasm treated with botulinum A toxin injection].
J. Wang (1998)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
10.1007/PL00007849
Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm
R. Çakmur (2002)
10.1006/exnr.2000.7583
Botulinum A Toxin: Dysport Improvement of Biological Availability
H. Bigalke (2001)
Botulinum isn't just a poison anymore. Botulinum toxin in treatment of strabismus and essential blepharospasm.
G. Cibis (1985)
10.1016/0022-3999(85)90012-1
Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches.
M. Faulstich (1985)
10.1097/01.IOP.0000065203.88182.CF
Benign Essential Blepharospasm Among Residents of Olmsted County, Minnesota, 1976 to 1995: An Epidemiologic Study
E. Bradley (2003)
10.5935/0004-2749.19980098
Tratamento do espasmo facial unilateral com toxina botulínica tipo A
M. D. C. Cunha (1998)
10.1111/j.1524-4725.1998.tb04098.x
Treatment of Hyperfunctional Lines of the Face with Botulinum Toxin A
W. Binder (1998)
Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
L. Chang (1999)
10.4088/JCP.V61N0210
Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases.
H. Levin (2000)
10.1136/jnnp.59.3.309
Pretarsal application of botulinum toxin for treatment of blepharospasm.
M. Aramideh (1995)
[Long-term treatment with botulinum toxin: dosage, treatment schedules and costs].
P. Schnider (1999)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1590/S0004-282X2003000400015
[Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
F. Cardoso (2003)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
10.1136/bjo.87.1.54
Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye
J. Horwath-Winter (2003)
10.1136/jnnp.51.6.767
Blepharospasm: a review of 264 patients.
F. Grandas (1988)
10.1093/QJMED/95.8.493
Hemifacial spasm and involuntary facial movements.
N. Tan (2002)
10.1176/AJP.155.4.555
Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm.
A. Broocks (1998)



This paper is referenced by
10.1590/S0004-282X2010000400006
Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience.
E. Barbosa (2010)
10.1590/S0034-72802011000600005
Análise da ceratometria corneana em pacientes portadores de espasmo hemifacial
Ivana Cardoso Pereira (2011)
10.1590/0004-282X20160191
Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated.
Jean Pierre Mette Batisti (2017)
10.1590/S0004-27492011000600006
Aberrações ópticas de alta ordem em pacientes com distonias faciais tratados com toxina botulínica
Mariann Midori Yabiku (2011)
10.1590/S0004-27492008000600027
Efeitos adversos associados à aplicação de toxina botulínica na face: revisão sistemática com meta-análise
R. Zagui (2008)
[Adverse effects associated with facial application of botulinum toxin: a systematic review with meta-analysis].
R. Zagui (2008)
10.22290/jbnc.v23i3.1197
Resultados tardios da descompressão microvascular do nervo facial pela artéria vertebral Long-term Outcomes of Facial Nerve Microvascular Decompression by Vertebral Artery
José Nazareno (2012)
10.1590/s0004-27492011000600006
[Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Mariann Midori Yabiku (2011)
[Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Fernanda Castro de Oliveira (2010)
A utilização da toxina botulínica tipo a para alcançar a estética facial
D. M. Barbosa (2020)
10.1007/978-1-4614-0971-7_21
Essential Blepharospasm and Hemifacial Spasm
Ilya M. Leyngold (2012)
10.1590/S0004-27492006000500016
Custos e eficácia da toxina botulínica tipo A no tratamento do blefaroespasmo essencial e espasmo hemifacial
Cintia Gomes Galvão Lasalvia (2006)
Semantic Scholar Logo Some data provided by SemanticScholar